Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration

Author： Comer Grant M   Ciulla Thomas A   Heier Jeffery S   Criswell Mark H  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.10, Iss.1, 2005-02, pp. : 119-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration

By Grant M. Comer  

Drugs & Aging, Vol. 21, Iss. 15, 2004-01 ,pp. : 967-992

Adis International

Access to resources Recommend Favorite

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

By Stewart Michael W  

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

Pegaptanib in exudative age-related macular degeneration: profile report

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 12, 2005-12 ,pp. : 6-8

Adis International

Access to resources Recommend Favorite

Pegaptanib in Exudative Age-Related Macular Degeneration: A Viewpoint by Steven Schwartz

By Schwartz Steven  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1578-1579

Adis International

Access to resources Recommend Favorite